Loading
Life sciences · Journal article
World Journal of Pharmaceutical Research · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Liposomes are phospholipid vesicles that have proven to be promising drug delivery systems, capable of carrying both hydrophilic and hydrophobic therapeutic agents. They have been used in a diverse array of pharmaceutical applications because of their biocompatibility, biodegradability, and ability to enhance drug solubility, stability, bioavailability, and therapeutic effects. New developments in liposomal technology, such as PEGylated liposomes, actively targeted liposomes, and stimulus-responsive liposomes, have greatly improved circulation time, site-specific delivery, and controlled drug release. With these developments, liposomes are being used in cancer treatment, vaccine delivery, fungal treatment, pain therapy, eye delivery, and transdermal drug delivery. Although they offer benefits, they also face challenges, including stability, drug leakage, manufacturing complexity, and production scale.